PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
Pre-publication versions of this article are available by contacting email@example.com.
|2 Jul 2012||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|27 Aug 2012||Reviewed||Reviewer Report - William Schelman|
|4 Sep 2012||Reviewed||Reviewer Report - James Cleary|
|4 Sep 2012||Reviewed||Reviewer Report - Wan-Teck Lim|
|3 Oct 2012||Author responded||Author comments - Mark McKeage|
|Resubmission - Version 3|
|3 Oct 2012||Submitted||Manuscript version 3|
|18 Oct 2012||Author responded||Author comments - Mark McKeage|
|Resubmission - Version 4|
|18 Oct 2012||Submitted||Manuscript version 4|
|23 Oct 2012||Editorially accepted|
|25 Oct 2012||Article published||10.1186/1471-2407-12-496|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.